ReviewThe Indian journal of medical research2017
Extensively drug-resistant tuberculosis in India: Current evidence on diagnosis & management.
Review in The Indian journal of medical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04923958 (Rapid Research in Diagnostics Development for TB Network), which is not on this map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) Study
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A systematic review on extensively drug-resistant tuberculosis from 2009 to 2020: special emphases on treatment outcomes.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023Pooled it
- Is latent tuberculosis infection challenging in Iranian health care workers? A systematic review and meta-analysis.PloS one · 2019Pooled it
- Strategies and Recent Advances in Tackling Antibacterial Resistance in India: A Comprehensive Narrative Review.Cureus · 2025Review
- Treatment Outcome of Drug-Resistant Skeletal Tuberculosis: A Retrospective Analysis.Indian journal of orthopaedics · 2024Article
- Micro-nanoemulsion and nanoparticle-assisted drug delivery against drug-resistant tuberculosis: recent developments.Clinical microbiology reviews · 2023Review
- In Silico Drug Repurposing Studies for the Discovery of Novel Salicyl-AMP Ligase (MbtA)Inhibitors.Pathogens (Basel, Switzerland) · 2023Article
- Assessment of the Association of Vitamin D and the Risk of Tuberculosis among End-Stage Kidney Disease Population.Life (Basel, Switzerland) · 2022Article
- HupB, a nucleoid-associated protein, is critical for survival ofFrontiers in microbiology · 2022Article
- Direct detection of resistance to fluoroquinolones/SLIDs in sputum specimen by GenoType MTBDRsl v.2.0 assay A study from Eastern Uttar Pradesh, India.Annals of clinical microbiology and antimicrobials · 2021Article
- Linezolid-resistantThe Indian journal of medical research · 2021Article
- Up regulated virulence genes in M. tuberculosis H37Rv gleaned from genome wide expression profiles.Bioinformation · 2021Article
- Molecular characterization of mutations associated with resistance to second line drugs in Mycobacterium tuberculosis patients from Casablanca, Morocco.Revista do Instituto de Medicina Tropical de Sao Paulo · 2021Article
- Prediction of Transcription Factors and Their Involvement in Regulating Rifamycin Production inIndian journal of microbiology · 2020Article
- Treatment outcomes of patients with MDR-TB in Nepal on a current programmatic standardised regimen: retrospective single-centre study.BMJ open respiratory research · 2020Article
- Inhibitors of energy metabolism interfere with antibiotic-induced death in mycobacteria.The Journal of biological chemistry · 2019Article
- Molecular detection of rifampin, isoniazid, and ofloxacin resistance in Iranian isolates ofInfection and drug resistance · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emergence of extensively drug-resistant tuberculosis (XDR-TB) has significantly threatened to jeopardize global efforts to control TB, especially in HIV endemic regions. XDR-TB is mainly an iatrogenically created issue, and understanding the epidemiological and risk factors associated with it is of paramount importance in curbing this menace. Emergence of this deadly phenomenon can be prevented by prompt diagnosis and effective treatment with second-line drugs in rifampicin-resistant TB (RR-TB) as well as multidrug-resistant TB (MDR-TB) patients. Optimal treatment of RR-TB, MDR-TB and XDR-TB cases alone will not suffice to reduce the global burden. The TB control programmes need to prioritize on policies focusing on the effective as well as rational use of first-line drugs in every newly diagnosed drug susceptible TB patients so as to prevent the emergence of drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.